Epigallocatechin‐3‐Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: Mechanisms of action
The Prostate2007Vol. 67(14), pp. 1576–1589
Citations Over TimeTop 10% of 2007 papers
Abstract
The attenuation of the AR, the down-regulation of potent growth factor IGF-1, modulation of inflammation biomarkers, and decrease in the MAPK signaling may contribute to the reduction in cell proliferation and induction of apoptosis and hence provide a biochemical basis for EGCG suppressing PCa without toxicity.
Related Papers
- → Are androgen receptor variants a substitute for the full-length receptor?(2015)124 cited
- → PRPF6 promotes androgen receptor/androgen receptor-variant 7 actions in castration-resistant prostate cancer cells(2020)15 cited
- → Pinostilbene inhibits full-length and splice variant of androgen receptor in prostate cancer(2023)5 cited
- → Androgen receptor: what we know and what we expect in castration-resistant prostate cancer(2018)29 cited
- → Dissecting the roles of the androgen receptor in prostate cancer from molecular perspectives(2017)25 cited